Sonny Gunawan

A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

M. Sherman, A. Hezel, A. El-Khoueiry, 2015, Clinical Cancer Research.

RDEA119: A potent and highly selective MEK inhibitor for the treatment of cancer

Shunqi Yan, R. Hamatake, G. Larson, 2007 .

A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

M. Sherman, A. Hezel, A. El-Khoueiry, 2015, Clinical Cancer Research.